Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026
Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026
Company Drug

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401

Fineline Cube Mar 18, 2025

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) announced receiving clinical trial approval for its investigational...

Company Medical Device

Lifetech Scientific’s Aortic Stent System Approved by China’s NMPA

Fineline Cube Mar 18, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) announced receiving market approval from the National Medical Products...

Company Deals

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services

Fineline Cube Mar 18, 2025

Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...

Company Drug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Fineline Cube Mar 18, 2025

Shanghai-based Rona Therapeutics Inc. announced receiving approval from the US Food and Drug Administration (FDA)...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis

Fineline Cube Mar 18, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clearance from the National Medical...

Company Drug

Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer

Fineline Cube Mar 18, 2025

China-based Alphamab Oncology (HKG: 9966) announced receiving Breakthrough Therapy Designation (BTD) from the National Medical...

Company Deals

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio

Fineline Cube Mar 17, 2025

On March 17, 2025, EsoBiotec SA announced a definitive acquisition agreement with AstraZeneca (NASDAQ: AZN)....

Company Deals

AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies

Fineline Cube Mar 17, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered...

Company Drug

Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan

Fineline Cube Mar 17, 2025

US-based giant Merck & Co., Inc. (NYSE: MRK) announced receiving approval from the Hainan Medical...

Company Drug

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment

Fineline Cube Mar 17, 2025

Shanghai-based Visirna Therapeutics announced positive topline results from the Phase III study of plozasiran in...

Company Medical Device

ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval

Fineline Cube Mar 17, 2025

China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...

Company Deals Drug

Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific

Fineline Cube Mar 17, 2025

Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...

Company

Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy

Fineline Cube Mar 17, 2025

California-based Phenomenex, a leading manufacturer of chromatography consumables, announced the inauguration of its R&D center...

Company Drug

BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma

Fineline Cube Mar 17, 2025

US giant Bristol-Myers Squibb (BMS; NYSE: BMY) announced receiving another indication approval from the European...

Company Deals

Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline

Fineline Cube Mar 17, 2025

Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China,...

Company Drug

Life Molecular Imaging Launches Neuraceq in Hong Kong for Alzheimer’s Detection

Fineline Cube Mar 17, 2025

Life Molecular Imaging Ltd., a subsidiary of South Africa’s Life Healthcare Group focused on PET...

Company Drug

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study

Fineline Cube Mar 17, 2025

Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...

Company Medical Device

Inari Medical Wins NMPA Approval for Thrombectomy Stent System in China

Fineline Cube Mar 17, 2025

US-based Inari Medical, Inc. (NASDAQ: NARI), set to be acquired by Stryker (NYSE: SYK), announced...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Tegileridine Approved for Postoperative Pain Management

Fineline Cube Mar 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the...

Company Drug

Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval

Fineline Cube Mar 17, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd announced receiving clinical approval from the National Medical Products...

Posts pagination

1 … 232 233 234 … 703

Recent updates

  • AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
  • WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
  • Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing
  • Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing
  • CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.